65 mtDNA Point Mutations Plus Large Deletions Panel
New York
Approved
Conditions
- Chronic Intestinal Pseudoobstruction with Myopathy and Ophthalmoplegia (CIPO)
- Chronic Progressive External Ophthalmoplegia (CPEO)
- Diabetes and Hearing Loss
- Kearns-Sayre Syndrome (KSS)
- Lactic acidosis
- Lebers Hereditary Optic Neuropathy (LHON)
- Maternally Inherited Deafness or Aminoglycoside-Induced Deafness
- Maternally Inherited Diabetes and Deafness (MIDD)
- Maternally Inherited Diabetes Mellitus (MIDM)
- Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-Like Episodes (MELAS)
- Mitochondrial Myopathy (MM)
- Mitochondrial Neurogastrointestinal Encephalopathy Syndrome (MNGIE)
- Myoclonic Epilepsy with Ragged-Red Fibers (MERRF)
- Neurogenic Weakness with Ataxia and Retinitis Pigmentosa (NARP)
- Pearson Syndrome
- Sensorineural Hearing Loss (SNHL)
Clinical Utility
- Molecular confirmation of a clinical diagnosis
- Testing of patients suspected of having a mitochondrial disorder
Lab Method
- Next-Gen Sequencing
Important Information
Test Code
704
CPT Codes*
81401x2, 81465x1, 81479x1
ABN Required
No
Turnaround Time**
3-4 weeks
Preferred Specimen
Alternative Specimen
*The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.
**Reporting times are typical and begin once the sample(s) are received at the GeneDx laboratory, but could be extended in situations outside GeneDx’s reasonable control.
Billing
Targeted Variant Testing